CAMBRIDGE, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (SURF) (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor ...

LONDON, United Kingdom — After years of clinical trial failures, an anti-interferon antibody, anifrolumab, has been shown to dramatically reduce disease activity in extrarenal systemic lupus ...